Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis

1. A method of determining pulmonary disease progression severity in a subject having cystic fibrosis and treating the subject, wherein the subject has experienced a pulmonary exacerbation, the method comprising

a. obtaining a whole blood sample from the subject at the time of pulmonary exacerbation;

b. detecting the mRNA expression level of each of the following genes: TLR2, ADAM9, PLXND1, CD163, CD36, CD64, CSPG2, IL32, HPSE, HCA112;

c. determining the severity of the pulmonary disease progress in the subject by calculating a disease risk score of mild, moderate or severe pulmonary disease progression based on the subject's combined mRNA expression level of the genes from step (b) at the time of pulmonary exacerbation, wherein the subject's calculated disease risk score correlates to the risk score for mild, moderate or severe pulmonary disease progression at exacerbation; and

d. treating the subject with treatments effective for treating mild, moderate or severe pulmonary disease progression.

2. The method of claim 1 , wherein the mRNA expression level of the genes is detected by quantitative PCR or flow cytometery.

3. The method of claim 1 , wherein a subject having severe pulmonary exacerbation disease progression will have an increased risk of morbidity.

4. The method of claim 1 , wherein a subject having severe pulmonary exacerbation disease progression will have an increased risk of mortality.

5. The method of claim 1 , wherein a subject having severe or moderate pulmonary exacerbation disease progression will have an increased risk for exacerbation recurrence.

6. The method of claim 1 , wherein a subject having severe or moderate pulmonary exacerbation disease progression will have a shorter interval of exacerbation free time.

7. The method of claim 1 , further comprising measuring the subject's forced expiratory volume (FEV 1 ) and/or C-reactive protein (CRP) levels.